Precision Biosciences INC

Precision BioSciences has appointed a new Chief Operating Officer and Chief Financial Officer, effective August 1, 2026, to support program advancement.

Precision BioSciences reports clinical highlights for PBGENE-HBV and initiates the FUNCTION-DMD trial, targeting year-end updates for both programs.

Precision BioSciences has amended its loan and security agreement, extending the maturity date of its term loan to December 31, 2029.

Precision BioSciences presented new clinical data from its PBGENE-HBV trial at EASL 2026, showing direct elimination of cccDNA in chronic hepatitis B patients.

Precision BioSciences held its annual stockholder meeting, approving key plan amendments and director elections.

Precision BioSciences reported Q1 2026 results, highlighting advancements in its gene editing programs for Hepatitis B and Duchenne Muscular Dystrophy, alongside a cash balance projected to fund operations through 2028.

Precision BioSciences Inc. reported its first quarter 2026 financial results, highlighting significant revenue growth driven by collaboration agreements and continued investment in its lead gene editing programs.

Precision BioSciences reported a significant net loss in Q3 2025, driven by reduced collaboration revenue, while advancing its lead gene editing programs and extending its cash runway into late 2027.

Precision BioSciences reported a significant net loss in Q2 2025 due to reduced collaboration revenue, while highlighting positive clinical and preclinical data for its gene editing programs and extending its cash runway.

Precision BioSciences announces its Q1 2025 financial results, emphasizing advancements in its in vivo gene editing therapies, particularly PBGENE-HBV and PBGENE-DMD.

Precision BioSciences reports a net loss of $16.4 million for Q3 2024, while highlighting progress in its in vivo gene editing programs and strategic collaborations.

Precision BioSciences reports a significant increase in revenue for the second quarter of 2024, primarily driven by collaboration agreements and strategic transactions.

Precision BioSciences' 2025 Annual Report reveals a significant net loss and revenue decline, offset by promising clinical advancements in its gene editing pipeline and a successful capital raise.

Precision BioSciences advances its in vivo gene editing therapies, including PBGENE-HBV clinical trial initiation, and reports a net income of $7.2 million for the year ended December 31, 2024.

Precision BioSciences' 10-K filing highlights a strategic shift towards in vivo gene editing, divesting its CAR T platform and focusing on its ARCUS technology for genetic and infectious diseases.

Director Melinda Brown was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Precision BioSciences director Stanley Frankel was granted 20,979 restricted stock units as part of standard equity compensation.

Director Geno J. Germano was granted 20,979 restricted stock units as part of the company's equity compensation program.

Director Shari Lisa Pire was granted 20,979 restricted stock units by Precision BioSciences, Inc.

Precision BioSciences director Kevin Buehler was granted 20,979 restricted stock units as part of standard equity compensation.

Precision BioSciences reports the grant of 57,389 restricted stock units to Chief Research Officer J. Jefferson Smith.

Precision BioSciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, detailing proposals including director elections, auditor ratification, executive compensation, and equity plan amendments.

Precision BioSciences has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Precision BioSciences will hold its 2025 annual meeting of stockholders on May 28, 2025, via a virtual webcast.

Precision BioSciences has filed a definitive proxy statement with the SEC.

Precision BioSciences announces its 2024 annual meeting of stockholders to be held virtually on June 4, 2024, outlining proposals for director elections, auditor ratification, incentive plan amendments, and potential meeting adjournment.

Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Precision BioSciences, Inc. common stock.

Lynx1 Capital Management LP and Weston Nichols have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Precision BioSciences Inc. common stock.

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 7.63% in Precision BioSciences, Inc. common stock as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have reported a 4.1% beneficial ownership stake in Precision BioSciences Inc., totaling 993,913 shares of common stock.

Octagon Capital Advisors LP, along with its Master Fund and Ting Jia, reported a 9.99% beneficial ownership stake in Precision BioSciences, Inc. as of December 31, 2025.

Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 8.88% in Precision Biosciences Inc. as of December 31, 2025.